A Precision Medicine Approach to Improve Cancer Rehabilitation’s Impact and Integration with Cancer Care and Optimize Patient Wellness

  • Catherine M. AlfanoEmail author
  • David S. Zucker
  • Mackenzi Pergolotti
  • Kirsten K. Ness
  • Lee W. Jones
  • Nathan D. Price
  • Kathryn H. Schmitz
  • Jennifer A. Ligibel
Cancer Rehabilitation (MD Stubblefield, Section Editor)
Part of the following topical collections:
  1. Cancer Rehabilitation


Purpose of Review

Many patients treated for cancer develop toxicities that go unaddressed, limiting their functioning, health, quality of life, and ability to work. This review describes how to optimize patient functioning and quality of life by preventing toxicities where possible or treating them early to reduce impairment and prevent disability.

Recent Findings

Increasing the impact of cancer rehabilitation on preventing and treating toxicity requires filling research gaps and better integrating rehabilitation with cancer care.


We must understand risk factors and the underlying biology driving impairments, disability, and individual response to intervention. Then, we need to integrate these data and implement screening of all patients throughout treatment and beyond to (1) monitor biological changes that would lead to downstream impairments and facilitate referrals for personalized rehabilitation interventions to prevent these; (2) where prevention is impossible, screen for impairments and prescribe interventions to treat them early; or (3) intervene to prevent disability resulting from impairments that cannot be prevented or treated.


Cancer Oncology Survivorship Toxicity Precision medicine Rehabilitation Cancer rehabilitation 


Compliance with Ethical Standards

Conflict of Interest

Lee W. Jones reports grants from the National Cancer Institute, the Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748), and ATKIV Against Cancer.

Nathan D. Price is cofounder of and holds stock with Arivale, reports grants from Jassen Pharmaceuticals, reports grants from Amgen, reports grants from GBM, and reports grants from and serves as board member for Habit.

Kathryn H. Schmitz is supported by research grants from the National Cancer Institute and the Chinchilli Family Foundation.

Catherine M. Alfano, David S. Zucker, Mackenzi Pergolotti, Kirsten K. Ness, and Jennifer A. Ligibel declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of important •• Of major importance

  1. 1.
    • American Cancer Society. Cancer facts & figures 2016. Atlanta: American Cancer Society; 2016. An estimated 1,685,210 new cancer cases are expected to be diagnosed in the USA in 2016.Google Scholar
  2. 2.
    Stubblefield MD, O’Dell MW, editors. Cancer rehabilitation principles and practice. New York: Demos Medical Publishing; 2009.Google Scholar
  3. 3.
    Silver JK, Baima J, Mayer RS. Impairment-driven cancer rehabilitation: an essential component of quality care and survivorship. CA Cancer J Clin. 2013;63(5):295–317.CrossRefPubMedGoogle Scholar
  4. 4.
    Ness KK, Mertens AC, Hudson MM, Wall MM, Leisenring WM, Oeffinger KC, et al. Limitations on physical performance and daily activities among long-term survivors of childhood cancer. Ann Intern Med. 2005;143(9):639–47.CrossRefPubMedGoogle Scholar
  5. 5.
    Ness KK, Wall MM, Oakes JM, Robison LL, Gurney JG. Physical performance limitations and participation restrictions among cancer survivors: a population-based study. Ann Epidemiol. 2006;16(3):197–205.CrossRefPubMedGoogle Scholar
  6. 6.
    Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in transition. Washington DC: National Academies Press; 2006.Google Scholar
  7. 7.
    Hewitt M, Weiner SL, Simone JV, editors. Childhood cancer survivorship: improving care and quality of Life. Washington, DC: The National Academies Press; 2003.Google Scholar
  8. 8.
    Holmes HM, Nguyen HT, Nayak P, Oh JH, Escalante CP, Elting LS. Chronic conditions and health status in older cancer survivors. Eur J Intern Med. 2014;25(4):374–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Smith AW, Reeve BB, Bellizzi KM, Harlan LC, Klabunde CN, Amsellem M, et al. Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev. 2008;29(4):41–56.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Leach CR, Weaver KE, Aziz NM, Alfano CM, Bellizzi KM, Kent EE, et al. The complex health profile of long-term cancer survivors: prevalence and predictors of comorbid conditions. J Cancer Surviv. 2015;9(2):239–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Cheville AL, Beck LA, Petersen TL, Marks RS, Gamble GL. The detection and treatment of cancer-related functional problems in an outpatient setting. Support Care Cancer. 2009;17(1):61–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Adler NE, Page A. National Institue of Medicine (U. S.) Committee on Psychosocial Services to Cancer Patients/Families in a Community Setting. Cancer care for the whole patient: meeting psychosocial health needs. Washington, D.C.: National Academies Press; 2008. xxii, 429 p.Google Scholar
  13. 13.
    Schmitz KH, Speck RM, Rye SA, DiSipio T, Hayes SC. Prevalence of breast cancer treatment sequelae over 6 years of follow-up: the Pulling Through Study. Cancer. 2012;118(8 Suppl):2217–25.CrossRefPubMedGoogle Scholar
  14. 14.
    Jones LW, Courneya KS, Mackey JR, Muss HB, Pituskin EN, Scott JM, et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol. 2012;30(20):2530–7.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol. 2000;18(4):893–903.CrossRefPubMedGoogle Scholar
  16. 16.
    Zebrack BJ, Yi J, Petersen L, Ganz PA. The impact of cancer and quality of life for long-term survivors. Psychooncology. 2008;17(9):891–900.CrossRefPubMedGoogle Scholar
  17. 17.
    Bodurka-Bevers D, Basen-Engquist K, Carmack CL, Fitzgerald MA, Wolf JK, de Moor C, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78(3 Pt 1):302–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Islam T, Dahlui M, Majid HA, Nahar AM, Mohd Taib NA, Su TT, et al. Factors associated with return to work of breast cancer survivors: a systematic review. BMC Public Health. 2014;14(Suppl 3):S8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22(17):3524–30.CrossRefPubMedGoogle Scholar
  20. 20.
    •• Brown JC, Harhay MO, Harhay MN. Patient-reported versus objectively-measured physical function and mortality risk among cancer survivors. J Geriatr Oncol. 2016;7(2):108–15. Sixty-six percent of cancer survivors reported at least one physical limitation. Each additional functional limitation was associated with 19% increased risk of death CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sehl M, Lu X, Silliman R, Ganz PA. Decline in physical functioning in first 2 years after breast cancer diagnosis predicts 10-year survival in older women. J Cancer Surviv. 2013;7(1):20–31.CrossRefPubMedGoogle Scholar
  22. 22.
    • American Cancer Society. Cancer treatment and survivorship facts & figures 2016–2017. Atlanta, GA: American Cancer Society; 2016. An estimated 15.5 million cancer survivors were alive in the USA as of January 1, 2016. The population of cancer survivors is expected to reach 20.3 million by January 1, 2026.Google Scholar
  23. 23.
    • National Cancer Institute. Cancer Moonshot Blue Ribbon Panel Report. [Available from: 2016. Minimizing cancer treatment’s debilitating side effects is listed as one of the key areas where the NCI Blue Ribbon Panel recommends that we make 10 years of progress in 5 years.
  24. 24.
    Mewes JC, Steuten LM, Ijzerman MJ, van Harten WH. Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review. Oncologist. 2012;17(12):1581–93.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Duijts SF, Faber MM, Oldenburg HS, van Beurden M, Aaronson NK. Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors—a meta-analysis. Psychooncology. 2011;20(2):115–26.CrossRefPubMedGoogle Scholar
  26. 26.
    Fode M, Serefoglu EC, Albersen M, Sonksen J. Sexuality following radical prostatectomy: is restoration of erectile function enough? Sex Med Rev. 2016.Google Scholar
  27. 27.
    Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012;8:CD008465.Google Scholar
  28. 28.
    Furmaniak AC, Menig M, Markes MH. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. 2016;9:CD005001.PubMedGoogle Scholar
  29. 29.
    Jones LW, Alfano CM. Exercise-oncology research: past, present, and future. Acta Oncol. 2013;52(2):195–215.CrossRefPubMedGoogle Scholar
  30. 30.
    Lehmann JF, DeLisa JA, Warren CG, deLateur BJ, Bryant PL, Nicholson CG. Cancer rehabilitation: assessment of need, development, and evaluation of a model of care. Arch Phys Med Rehabil 1978;59(9):410–419.Google Scholar
  31. 31.
    Alfano CM, Ganz PA, Rowland JH, Hahn EE. Cancer survivorship and cancer rehabilitation: revitalizing the link. J Clin Oncol. 2012;30(9):904–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Alfano CM, Cheville AL, Mustian K. Developing high-quality cancer rehabilitation programs: a timely need. Am Soc Clin Oncol Educ Book. 2016;35:241–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Stout NL, Silver JK, Raj VS, Rowland J, Gerber L, Cheville A, et al. Toward a national initiative in cancer rehabilitation: recommendations from a subject matter expert group. Arch Phys Med Rehabil. 2016.Google Scholar
  34. 34.
    Silver JK, Raj VS, Fu JB, Wisotzky EM, Smith SR, Kirch RA. Cancer rehabilitation and palliative care: critical components in the delivery of high-quality oncology services. Support Care Cancer. 2015;23(12):3633–43.CrossRefPubMedGoogle Scholar
  35. 35.
    •• Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–5. This article articulates a thoughtful vision for the new US initiative on precision medicine CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Reyes-Gibby CC, Wang J, Silvas MR, Yu R, Yeung SC, Shete S. MAPK1/ERK2 as novel target genes for pain in head and neck cancer patients. BMC Genet. 2016;17:40.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30(30):3675–86.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Fu MR, Conley YP, Axelrod D, Guth AA, Yu G, Fletcher J, et al. Precision assessment of heterogeneity of lymphedema phenotype, genotypes and risk prediction. Breast. 2016.Google Scholar
  39. 39.
    Bower JE, Ganz PA, Irwin MR, Castellon S, Arevalo J, Cole SW. Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol. 2013;31(13):1656–61.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Doong SH, Dhruva A, Dunn LB, West C, Paul SM, Cooper BA, et al. Associations between cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression in patients prior to breast cancer surgery. Biol Res Nurs. 2015;17(3):237–47.CrossRefPubMedGoogle Scholar
  41. 41.
    Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, et al. ESR1 and ESR2 polymorphisms in the BIG 1–98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. Breast Cancer Res Treat. 2015;154(3):543–55.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, et al. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. Breast Cancer Res Treat. 2015;154(2):263–73.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Moriyama T, Relling MV, Yang JJ. Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood. 2015;125(26):3988–95.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD, et al. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Breast Cancer Res Treat. 2015;152(1):67–76.CrossRefPubMedGoogle Scholar
  45. 45.
    Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016;82(3):683–95.CrossRefPubMedGoogle Scholar
  46. 46.
    Reyes-Gibby CC, Wang J, Yeung SC, Shete S. Informative gene network for chemotherapy-induced peripheral neuropathy. BioData Min. 2015;8:24.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26(6):971–82.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919–25.CrossRefPubMedGoogle Scholar
  49. 49.
    Kim HJ, Barsevick AM, Fang CY, Miaskowski C. Common biological pathways underlying the psychoneurological symptom cluster in cancer patients. Cancer Nurs. 2012;35(6):E1–E20.CrossRefPubMedGoogle Scholar
  50. 50.
    Miller GE, Chen E, Fok AK, Walker H, Lim A, Nicholls EF, et al. Low early-life social class leaves a biological residue manifested by decreased glucocorticoid and increased proinflammatory signaling. Proc Natl Acad Sci U S A. 2009;106(34):14716–21.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Flores AM, Nelson J, Sowles L, Bienenstock K, Blot WJ. Physical impairments and physical therapy services for minority and low-income breast cancer survivors. Springerplus. 2016;5(1):1227.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Schrijvers CT, Coebergh JW, Mackenbach JP. Socioeconomic status and comorbidity among newly diagnosed cancer patients. Cancer. 1997;80(8):1482–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al.. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2016.Google Scholar
  54. 54.
    Mantarro S, Rossi M, Bonifazi M, D'Amico R, Blandizzi C, La Vecchia C, et al. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med. 2016;11(1):123–40.CrossRefPubMedGoogle Scholar
  55. 55.
    Braithwaite D, Satariano WA, Sternfeld B, Hiatt RA, Ganz PA, Kerlikowske K, et al. Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst. 2010;102(19):1468–77.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Bennett JA, Winters-Stone KM, Dobek J, Nail LM. Frailty in older breast cancer survivors: age, prevalence, and associated factors. Oncol Nurs Forum. 2013;40(3):E126–34.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Mullen JT, Davenport DL, Hutter MM, Hosokawa PW, Henderson WG, Khuri SF, et al. Impact of body mass index on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery. Ann Surg Oncol. 2008;15(8):2164–72.CrossRefPubMedGoogle Scholar
  58. 58.
    Wu XS, Wu WG, Li ML, Yang JH, Ding QC, Zhang L, et al. Impact of being overweight on the surgical outcomes of patients with gastric cancer: a meta-analysis. World J Gastroenterol. 2013;19(28):4596–606.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Imayama I, Alfano CM, Neuhouser ML, George SM, Wilder Smith A, Baumgartner RN, et al. Weight, inflammation, cancer-related symptoms and health related quality of life among breast cancer survivors. Breast Cancer Res Treat. 2013;140(1):159–76.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    LaVoy EC, Fagundes CP, Dantzer R. Exercise, inflammation, and fatigue in cancer survivors. Exerc Immunol Rev. 2016;22:82–93.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Alfano CM, Smith AW, Irwin ML, Bowen DJ, Sorensen B, Reeve BB, et al. Physical activity, long-term symptoms, and physical health-related quality of life among breast cancer survivors: a prospective analysis. J Cancer Surviv. 2007;1(2):116–28.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Smith AW, Alfano CM, Reeve BB, Irwin ML, Bernstein L, Baumgartner K, et al. Race/ethnicity, physical activity, and quality of life in breast cancer survivors. Cancer Epidemiol Biomark Prev. 2009;18(2):656–63.CrossRefGoogle Scholar
  63. 63.
    Paxton RJ, Phillips KL, Jones LA, Chang S, Taylor WC, Courneya KS, et al. Associations among physical activity, body mass index, and health-related quality of life by race/ethnicity in a diverse sample of breast cancer survivors. Cancer. 2012;118(16):4024–31.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Voskuil DW, van Nes JG, Junggeburt JM, van de Velde CJ, van Leeuwen FE, de Haes JC. Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients. Ann Oncol. 2010;21(10):2094–101.CrossRefPubMedGoogle Scholar
  65. 65.
    Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol. 2016;34(23):2743–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Jones LW, Liu Q, Armstrong GT, Ness KK, Yasui Y, Devine K, et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol. 2014;32(32):3643–50.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Brown JC, Schmitz KH. The prescription or proscription of exercise in colorectal cancer care. Med Sci Sports Exerc. 2014;46(12):2202–9.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Zhang X, Haggerty AF, Brown JC, Giuntoli 2nd R, Lin L, Simpkins F, et al. The prescription or proscription of exercise in endometrial cancer care. Gynecol Oncol. 2015;139(1):155–9.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Schootman M, Aft R, Jeffe DB. An evaluation of lower-body functional limitations among long-term survivors of 11 different types of cancers. Cancer. 2009;115(22):5329–38.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Paskett ED, Alfano CM, Davidson MA, Andersen BL, Naughton MJ, Sherman A, et al. Breast cancer survivors’ health-related quality of life: racial differences and comparisons with noncancer controls. Cancer. 2008;113(11):3222–30.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Rao D, Debb S, Blitz D, Choi SW, Cella D. Racial/ethnic differences in the health-related quality of life of cancer patients. J Pain Symptom Manag. 2008;36(5):488–96.CrossRefGoogle Scholar
  72. 72.
    Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced fibrosis: mechanisms and implications for therapy. J Cancer Res Clin Oncol. 2015;141(11):1985–94.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, et al. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain Behav Immun. 2013;30(Suppl):S126–34.CrossRefPubMedGoogle Scholar
  74. 74.
    • Mohile SG, Velarde C, Hurria A, Magnuson A, Lowenstein L, Pandya C, et al. Geriatric assessment-guided care processes for older adults: a Delphi consensus of geriatric oncology experts. J National Compr Cancer Netw. 2015;13(9):1120–30. This article describes the results of a Delphi study of content experts who agree that a comprehensive geriatric assessment should be used to determine cancer treatment plans to decrease the risk for chemotherapy toxicity.Google Scholar
  75. 75.
    Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz J-P, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241–52.CrossRefPubMedGoogle Scholar
  76. 76.
    Hurria A, Akiba C, Kim J, Mitani D, Loscalzo M, Katheria V, et al. Reliability, validity, and feasibility of a computer-based geriatric assessment for older adults with cancer. J Oncol Pract. 2016.Google Scholar
  77. 77.
    Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371–81.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82.CrossRefPubMedGoogle Scholar
  79. 79.
    Hudson MM, Mertens AC, Yasui Y, Hobbie W, Chen H, Gurney JG, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA. 2003;290(12):1583–92.CrossRefPubMedGoogle Scholar
  80. 80.
    Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014;32(12):1218–27.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Hudson MM, Oeffinger KC, Jones K, Brinkman TM, Krull KR, Mulrooney DA, et al. Age-dependent changes in health status in the Childhood Cancer Survivor cohort. J Clin Oncol. 2015;33(5):479–91.CrossRefPubMedGoogle Scholar
  82. 82.
    • Ness KK, Krull KR, Jones KE, Mulrooney DA, Armstrong GT, Green DM, et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study. J Clin Oncol. 2013;31(36):4496–503. Compared to siblings, survivors of childhood cancer were more likely to report poor general health, mental health, functional impairment, and activity limitations.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    de Labra C, Guimaraes-Pinheiro C, Maseda A, Lorenzo T, Millan-Calenti JC. Effects of physical exercise interventions in frail older adults: a systematic review of randomized controlled trials. BMC Geriatr. 2015;15:154.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev. 2012;11(3):390–8.CrossRefPubMedGoogle Scholar
  85. 85.
    Braam KI, van der Torre P, Takken T, Veening MA, van Dulmen-den Broeder E, Kaspers GJ. Physical exercise training interventions for children and young adults during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2013;4:CD008796.Google Scholar
  86. 86.
    Henderson TO, Ness KK, Cohen HJ. Accelerated aging among cancer survivors: from pediatrics to geriatrics. Am Soc Clin Oncol Educ Book. 2014:e423–30.Google Scholar
  87. 87.
    Hood L, Price ND. Demystifying disease, democratizing health care. Sci Transl Med. 2014;6(225):225ed5.CrossRefPubMedGoogle Scholar
  88. 88.
    Thiele I, Swainston N, Fleming RM, Hoppe A, Sahoo S, Aurich MK, et al. A community-driven global reconstruction of human metabolism. Nat Biotechnol. 2013;31(5):419–25.CrossRefPubMedGoogle Scholar
  89. 89.
    Wang Y, Eddy JA, Price ND. Reconstruction of genome-scale metabolic models for 126 human tissues using mCADRE. BMC Syst Biol. 2012;6:153.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Price ND, Shmulevich I. Biochemical and statistical network models for systems biology. Curr Opin Biotechnol. 2007;18(4):365–70.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle. 2015;6(2):115–24.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010;4(2):87–100.CrossRefPubMedGoogle Scholar
  93. 93.
    Jones LW, Hornsby WE, Freedland SJ, Lane A, West MJ, Moul JW, et al. Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer. Eur Urol. 2014;65(5):852–5.CrossRefPubMedGoogle Scholar
  94. 94.
    Jones LW. Precision oncology framework for investigation of exercise as treatment for cancer. J Clin Oncol. 2015;33(35):4134–7.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Jones LW, Kwan ML, Weltzien E, Chandarlapaty S, Sternfeld B, Sweeney C, et al. Exercise and prognosis on the basis of clinicopathologic and molecular features in early-stage breast cancer: the LACE and Pathways Studies. Cancer Res. 2016;76(18):5415–22.CrossRefPubMedGoogle Scholar
  96. 96.
    Meyerhardt JA, Ogino S, Kirkner GJ, Chan AT, Wolpin B, Ng K, et al. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009;15(18):5931–6.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Jones LW, Douglas PS, Khouri MG, Mackey JR, Wojdyla D, Kraus WE, et al. Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial. J Clin Oncol. 2014;32(23):2496–502.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Schaadt L, Christensen R, Kristensen LE, Henriksen M. Increased mortality in patients with severe COPD associated with high-intensity exercise: a preliminary cohort study. Int J Chron Obstruct Pulmon Dis. 2016;11:2329–34.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation. 2010;121(5):675–83.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Stout NL, Binkley JM, Schmitz KH, Andrews K, Hayes SC, Campbell KL, et al. A prospective surveillance model for rehabilitation for women with breast cancer. Cancer. 2012;118(8 Suppl):2191–200.CrossRefPubMedGoogle Scholar
  101. 101.
    Riley WT, Nilsen WJ, Manolio TA, Masys DR, Lauer M. News from the NIH: potential contributions of the behavioral and social sciences to the precision medicine initiative. Transl Behav Med. 2015;5(3):243–6.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    • Basch E, Wood WA, Schrag D, Sima CS, Shaw M, Rogak LJ, et al. Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. Clinical Trials. 2015. Use of tablet computers to report patient symptoms to oncology providers helped clinicians more accurately estimate patient symptoms and led to clinical actions for symptom management. Google Scholar
  103. 103.
    Wood WA, Deal AM, Abernethy A, Basch E, Battaglini C, Kim YH, et al. Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(3):450–9.CrossRefPubMedGoogle Scholar
  104. 104.
    Wildes TM, Depp B, Colditz G, Stark S. Fall-risk prediction in older adults with cancer: an unmet need. Support Care Cancer Off J Multinat Assoc Support Care Cancer. 2016;24(9):3681–4.Google Scholar
  105. 105.
    Ness KK, Hudson MM, Pui CH, Green DM, Krull KR, Huang TT, et al. Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer. 2012;118(3):828–38.CrossRefPubMedGoogle Scholar
  106. 106.
    Ness KK, Kaste SC, Zhu L, Pui CH, Jeha S, Nathan PC, et al. Skeletal, neuromuscular and fitness impairments among children with newly diagnosed acute lymphoblastic leukemia. Leuk Lymphoma. 2015;56(4):1004–11.CrossRefPubMedGoogle Scholar
  107. 107.
    Gurney JG, Kaste SC, Liu W, Srivastava DK, Chemaitilly W, Ness KK, et al. Bone mineral density among long-term survivors of childhood acute lymphoblastic leukemia: results from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer. 2014;61(7):1270–6.CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Krull KR, Brinkman TM, Li C, Armstrong GT, Ness KK, Srivastava DK, et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude Lifetime Cohort Study. J Clin Oncol. 2013;31(35):4407–15.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Ness KK, Morris EB, Nolan VG, Howell CR, Gilchrist LS, Stovall M, et al. Physical performance limitations among adult survivors of childhood brain tumors. Cancer. 2010;116(12):3034–44.CrossRefPubMedPubMedCentralGoogle Scholar
  110. 110.
    Ashford JM, Netson KL, Clark KN, Merchant TE, Santana VM, Wu S, et al. Adaptive functioning of childhood brain tumor survivors following conformal radiation therapy. J Neuro-Oncol. 2014;118(1):193–9.CrossRefGoogle Scholar
  111. 111.
    Fernandez-Pineda I, Hudson MM, Pappo AS, Bishop MW, Klosky JL, Brinkman TM, et al. Long-term functional outcomes and quality of life in adult survivors of childhood extremity sarcomas: a report from the St. Jude Lifetime Cohort Study. J Cancer Surviv. 2016.Google Scholar
  112. 112.
    Marina N, Hudson MM, Jones KE, Mulrooney DA, Avedian R, Donaldson SS, et al. Changes in health status among aging survivors of pediatric upper and lower extremity sarcoma: a report from the childhood cancer survivor study. Arch Phys Med Rehabil. 2013;94(6):1062–73.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Fauske L, Lorem G, Grov EK, Bondevik H. Changes in the body image of bone sarcoma survivors following surgical treatment—a qualitative study. J Surg Oncol. 2016;113(2):229–34.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media New York 2017

Authors and Affiliations

  • Catherine M. Alfano
    • 1
    Email author
  • David S. Zucker
    • 2
  • Mackenzi Pergolotti
    • 3
  • Kirsten K. Ness
    • 4
  • Lee W. Jones
    • 5
  • Nathan D. Price
    • 6
  • Kathryn H. Schmitz
    • 7
  • Jennifer A. Ligibel
    • 8
  1. 1.American Cancer Society, Inc.WashingtonUSA
  2. 2.Swedish Cancer InstituteSeattleUSA
  3. 3.Department of Occupational Therapy, College of Health and Human SciencesColorado State UniversityFort CollinsUSA
  4. 4.Department of Epidemiology and Cancer ControlSt. Jude Children’s Research HospitalMemphisUSA
  5. 5.Department of MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA
  6. 6.Institute for Systems BiologySeattleUSA
  7. 7.Department of Public Health SciencesPenn State College of MedicineHersheyUSA
  8. 8.Dana-Farber Cancer InstituteBostonUSA

Personalised recommendations